摘要:

AbstractTwenty-two patients with disseminated adenocarcinoma of the large bowel received therapy with 5-fluorouracil 800-1000 mg/m2as a 24 h infusion for 4 consecutive days with 60 mg/m2intravenous folinic acid administered every 6 hours. Major responses were seen in 3 of 20 (15%) evaluablepatients, for a median of 5 months. Mucositis was the major toxicity occurring in 80% of patients. Folinic acid resulted in an additional $960/m2per therapeutic course without improvement of response rate or survival at this dose and schedule.

ISSN:0735-7907    

DOI:10.3109/07357908809077039

出版商:Taylor&Francis    

年代:1988

数据来源: Taylor

摘要:

AbstractTwenty-three patients with advanced colorectal cancer were treated with folinic acid (200 mg/m2/day 1-5IV bolus injection) and 5-fluorouracil (400 mg/m2/day 1-5 IV in 15 minutes) every 28 days. Only three patients were pretreated. Objective response was observed in 6 (30%) of 20 evaluable patients (three complete and three partial responses). The median duration of response was 9 months (range 5-15) and time to disease progression ranged from 2 to 12 months (median 6 months). Median survival was 21 months (range 12-23+) for responders. Another 6 (30%) patients had stabilization of disease. Toxicity was generally gastrointestinal (mucositis, diarrhea, nausea); moderate leukopenia was noted. The response rate found in this study indicates that folinic acid administered in high doses enhances the effectiveness of 5-FU administered concomitantly in colorectal cancer.

ISSN:0735-7907    

DOI:10.3109/07357908809077040

出版商:Taylor&Francis    

年代:1988

数据来源: Taylor

摘要:

AbstractSeven patients developed a lung abscess and bronchopleural fistula after undergoing aggressive treatment of their lung cancer with radiotherapy±chemotherapy. These complications were preceded by a prodrome of recurrent bronchitis with increasing refractoriness to antibiotics, weight loss, fever, and generalized debilitation. Delays in definitive diagnosis and treatment often resulted from concern about the patients guarded cancer prognosis and misinterpretation of involved areas on x-rays and scans as being secondary to cancer rather than manifestations of treatment toxicity. Early surgical treatment utilizing local muscular flaps for bronchial stump reinforcement and restoration of chest wall continuity can successfully remedy these complications.

ISSN:0735-7907    

DOI:10.3109/07357908809077041

出版商:Taylor&Francis    

年代:1988

数据来源: Taylor

摘要:

AbstractThe effect of 1-β-D-arabinofuranosylcytosine (ara-C) on human bladder transitional cell carcinomas (TCC) was evaluated using nude mouse-grown established tumor lines SW-780, SW-1738, TCC-K1, and PR49. In the nude mouse tumors grew subcutaneously and evaluation of response to treatment was based on tumor volume analysis. Ara-C was administered intraperitoneally at a dosage of 250 mg/kg on days 1 to 4. All four tumor lines showed an initial phase of considerable regression during the treatment week. This was followed by a variable period of tumor growth arrest after which a gradual tumor regrowth was observed. The results of the present study suggested that ara-C may alter the growth rate of TCC, its effect becoming apparent during the time of its administration and for a short period thereafter. These observations indicate that more studies are warranted at both the experimental and clinical levels to further evaluate dosage and treatment schedule. The results of such additional studies may determine the importance of ara-C in the management of patients with bladder cancer.

ISSN:0735-7907    

DOI:10.3109/07357908809077042

出版商:Taylor&Francis    

年代:1988

数据来源: Taylor

摘要:

AbstractIn an attempt to differentiate between the biochemical characteristics of hormonal-dependent and independent gynecologic tumors, monoclonal antibodies (mABs) MBrl and MBr3 were used to detect tumor antigens. Steroid receptors and MBrl and MBr3 determinants were assayed independently in a double-blinded manner. Of the 45 gynecologic tumors analyzed, 16 of 20 (80%) with both progesterone receptors (PR) (>10 fm/mg protein) and estrogen receptors (ER) (>5 fm/mg protein) also contained high levels of MBrl determinant. However, these receptors were not quantitatively related to MBrl activity. The 15 of 17 (88%) tumors that contained receptors below the discriminant levels also had low or undetectable levels of MBrl activity. In tumors where only either PR or ER was present, 2 of 2 PR+/ER−tumors and 2 of 6PR−/ER+tumors expressed MBrl antigen. No relationship of MBr3 antigenic activity to the receptors was established. These results show that MBrl-recognized antigen is expressed largely in steroid receptor-positive tumors and these data suggest that either the antigen itself or its carrier protein may be regulated by estrogen. Like steroid receptors, MBrl antigens may have important prognostic value in gynecologic tumors.

ISSN:0735-7907    

DOI:10.3109/07357908809077043

出版商:Taylor&Francis    

年代:1988

数据来源: Taylor

摘要:

AbstractThe R3230AC rat mammary adenocarcinoma is a transplantable tumor model, which can be subcultured in vitro and does not metastasize spontaneously. However, when cell suspensions of this tumor are injected intravenously, multiple lung foci develop. These foci were used as source for a cell subpopulation. Prolonged exposure of the original tumor cell line to increasing levels of lectins (concanavalin A and wheat germ agglutinin) resulted in the development of a lectin-resistant sub-population. Through experimental in vitro exposure to the antiestrogenic compound tamoxifen citrate, a tolerant, karyotypically defined subpopulation was obtained. In the four cell lines studied, heterogeneity was observed in the following parameters: doubling time, steroid receptors, and median chromosome counts. Statistically discernible differences were found. This may represent a model for the effect of selective pressures in the tumor environment, such as endocrine manipulation, leading to the gradual development of resistant cell lines and treatment failure.

ISSN:0735-7907    

DOI:10.3109/07357908809077044

出版商:Taylor&Francis    

年代:1988

数据来源: Taylor

摘要:

AbstractINTRODUCTION The management of infections in cancer patients has evolved both conceptually and practically over the past twenty years. The advent of cytotoxic therapy opened new horizons on the road toward improved survival and even cure of some malignancies. With it, however, came an unprecedented and previously unrecognized array of abnormalities in host defense systems (Fig. 1), and consequendy, infectious complications that at first threatened to undermine any potential benefits of cancer therapy. The most profound of these alterations was granulocytopenia. Early on, it was recognized that successful management of the granulocytopenic patient required new and unique therapeutic guidelines. More traditional approaches for the treatment of infection in these patients, such as identification of a pathogen prior to institution of antibiotics, often led to disasterous consequences. Thus, the concept of empirical antibiotic therapy emerged, with routine empirical therapy now accepted as the standard of care when a granulocytopenic patient first becomes febrile. Early mortality from gram-negative sepsis has become relatively rare with this approach.

ISSN:0735-7907    

DOI:10.3109/07357908809077045

出版商:Taylor&Francis    

年代:1988

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357908809077046

出版商:Taylor&Francis    

年代:1988

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357908809077047

出版商:Taylor&Francis    

年代:1988

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357908809077048

出版商:Taylor&Francis    

年代:1988

数据来源: Taylor